Trial enrolment timelines are a bit interesting. A company...

Trial enrolment timelines are a bit interesting. A company corporate update in August indicated enrolment was around 75% at the start of August and then Megan Baldwin in an interview with the Opthalmology Times in early November indicated they had reached around 80% enrolment. I am fairly confident enrolment will be completed in both trials as per current company guidance I.e. before June 30th 2024.

Share daily trading volumes have increased considerably on the ASX and even more on noticeably on the Nasdaq since the announcement confirming further funding through the Carlyle scheme of arrangement. This additional funding would seem to be being perceived as an affirmation of Carlyle”s belief in the commercial prospects of Opt-302 given if the drug is not commercialised (and it will still need to be a commercial success) it will not recoup any of its investment. This is an all or nothing binary outcome.

I would not be surprised to see some form of corporate activity perhaps around commercialisation partnerships occur in 2024. The clock will start once trial enrolments are complete. I see the increasing americanisation of the management team as a definite positive. The new C and CFO have some serious runs on the board in the States and in itself I see their decision to link up with Opthea as an endorsement of the science behind OPT-302. I also suspect their ability to open ‘doors’ in the States is likely to exceed that of an Australian based CEO..

2024 is bound to be an interesting year for Opthea one way or another!